1-((Tert-butoxy)carbonyl)-3,3-dimethylpyrrolidine-2-carboxylic acid → 1-(tert-butoxycarbonyl)-3,3-dimethylprolyl-N-[5-chloro-2-(1H-tetraazol-yl)-benzyl]-L-prolinamide
반응식
[C:1]([O:5][C:6]([N:8]1[CH2:15][CH2:14][C:13]([CH3:17])([CH3:16])[CH:9]1[C:10]([OH:12])=O)=[O:7])([CH3:4])([CH3:3])[CH3:2].[Cl:18][C:19]1[CH:20]=[CH:21][C:22]([N:34]2[CH:38]=[N:37][N:36]=[N:35]2)=[C:23]([CH:33]=1)[CH2:24][NH:25][C:26](=[O:32])[C@@H:27]1[CH2:31][CH2:30][CH2:29][NH:28]1>C(Cl)CCl>[C:1]([O:5][C:6]([N:8]1[CH2:15][CH2:14][C:13]([CH3:17])([CH3:16])[C@H:9]1[C:10]([N:28]1[CH2:29][CH2:30][CH2:31][C@H:27]1[C:26]([NH:25][CH2:24][C:23]1[CH:33]=[C:19]([Cl:18])[CH:20]=[CH:21][C:22]=1[N:34]1[CH:38]=[N:37][N:36]=[N:35]1)=[O:32])=[O:12])=[O:7])([CH3:2])([CH3:3])[CH3:4]참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
실험 절차
The title compound was prepared as a mixture of diastereomers from 1-(tert-butoxycarbonyl)-3,3-dimethyl-dl-proline (61 mg, 0.25 mmol) and N-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]-L-prolinamide (Example 26, Step B, 95 mg, 0.25 mmol) essentially according to the EDC coupling procedure described in Example 39, Step D. The diastereomeric products were separated by reverse phase HPLC and were carried on directly to deprotection.